Skip to main content

Resveratrol and Propolis as Necrosis or Apoptosis Inducers in Human Prostate Carcinoma Cells

Buy Article:

$79.00 plus tax (Refund Policy)

Abstract:

Vegetables and fruit help the prevention and the therapy of several kinds of cancer because they contain micronutrients, a class of substances that have been shown to exhibit chemopreventive and chemotherapeutic activities. In the present study the effects of resveratrol (100 and 200 μM), a phytoalexin found in grapes, and of the ethanolic extract of propolis (50 and 100 μg/ml), a natural honeybee hive product, were tested in androgen-resistant prostate cancer cells (DU145), a cell line resembling the last stage of prostate carcinoma. A comparison between the activity of these micronutrients and vinorelbine bitartrate (Navelbine┬«), a semisynthetic drug normally used in the therapy of prostate cancer, was conducted. Several biochemical parameters were tested, such as cell viability (MTT assay), cell membrane integrity (lactate dehydrogenase release), cell redox status (nitric oxide formation, reactive oxygen species production, reduced glutathione levels), genomic DNA fragmentation (COMET assay) with special attention on the presence of apoptotic DNA damage (TUNEL test), and possible mitochondrial transmembrane potential alteration (ΔΨ). Our results point out the anticancer activity of resveratrol and propolis extract in human prostate cancer, exerting their cytotoxicity through two different types of cell death: necrosis and apoptosis, respectively. The data obtained suggest the possible use of these micronutrients both in alternative to classic chemotherapy, and in combination with very low dosage of vinorelbine (5 μM).

Keywords: DU 145; Human prostate cancer; Propolis; Resveratrol; Vinorelbine

Document Type: Research Article

DOI: http://dx.doi.org/10.3727/0965040041791437

Affiliations: 1: *Department of Biological Chemistry, Medicinal Chemistry and Molecular Biology, Via Passo Gravina 187- University of Catania, 95125 Catania, Italy 2: †Department of Physiological Sciences, Viale Andrea Doria, 6, Via Passo Gravina 187- University of Catania, 95125 Catania, Italy 3: ‡Department of Internal and Specialistic Medicine, Via Passo Gravina 187- University of Catania, 95125 Catania, Italy 4: ┬žDepartment of Experimental Pharmacology, Via D. Montesano 49, University of Naples Federico II, 80131 Naples, Italy

Publication date: January 1, 2004

More about this publication?
  • Formerly: Oncology Research Incorporating Anti-Cancer Drug Design
    Oncology Research Featuring Preclinical and Clincal Cancer Therapeutics publishes research of the highest quality that contributes to an understanding of cancer in areas of molecular biology, cell biology, biochemistry, biophysics, genetics, biology, endocrinology, and immunology, as well as studies on the mechanism of action of carcinogens and therapeutic agents, reports dealing with cancer prevention and epidemiology, and clinical trials delineating effective new therapeutic regimens.
cog/or/2004/00000014/00000009/art00002
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more